ObjectivesEarly discontinuation of antidepressant therapy is associated with relapse and increased costs. This exploratory study examined demographical and pretreatment clinical predictors of duloxetine (Eli Lilly and Company, Indianapolis, IN) treatment persistence in patients treated in real-world clinical ...
Late-life depression is a common, chronic and recurring disorder for which guidelines recommend long-term therapy. The safety and efficacy of duloxetine for the treatment of major depressive disorder (MDD) were evaluated using data from elderly patients (age ≥ 65 years; n = 101) who participate...
Objective The efficacy and safety of duloxetine, a dual reuptake inhibitor of serotonin (5-HT) and norepinephrine (NE), were evaluated in the treatment of major depressive disorder (MDD) and associated pain symptoms in patients age 55 and older. Methods Efficacy data were obtained from patients ...
Definitive comparisons are awaited, although duloxetine seemingly provides a useful alternative to SSRIs and other SNRIs for the treatment of MDD. It also appears to be an attractive option for MDD patients presenting with painful physical symptoms. Pharmacological Properties Duloxetine has a high affin...
Primary care patients with CMP will be randomized to one of three treatment arms: (1) combination treatment (duloxetine and web-based self-guided CBT) with phone-based MI, (2) combination treatment without phone-based MI, and (3) duloxetine therapy alone. Randomization will be conducted in ...
BACKGROUND: Late-life depression is a common, chronic and recurring disorder for which guidelines recommend long-term therapy. The safety and efficacy of duloxetine for the treatment of major depressive disorder (MDD) were evaluated using data from elderly patients (age >/= 65 years; n = 101)...
Monitor BP periodically during duloxetine therapy. Monitor patients for possible worsening of depression, suicidality, or unusual changes in behavior, especially at the beginning of therapy or during periods of dosage adjustment. Monitor patients for serotonin syndrome. Regular monitoring of weight and ...
Of the 350 subjects, 307 continued to the double-blind phase where they were randomized to receive either duloxetine 60 mg daily or duloxetine 120 mg daily for 52 weeks. In the initial open-label phase, 34.8% of patients responded to therapy, and all efficacy outcome measures showed ...
Development of original analytical methods for the therapeutic drug monitoring of CNS druges: Antipsychotics, Antidepressants and Anxiolytics-hypnotics Great strides have been made in the last few years in the pharmacological treatment of neuropsychiatric disorders, with the introduction into the therapy of...
62% of the original sample completed the ten week therapy.13 The third study utilized the same inclusion and exclusion criteria as the second study. Besides that, third study also excluded patients meeting criteria for any Axis II disorder or having history of antisocial behavior. In the third ...